Loading...
Loading...
PHAR| Name | Value |
|---|---|
| Revenues | 94.4M |
| Cost of Revenue | 9.1M |
| Gross Profit | 85.3M |
| Operating Expense | 74.0M |
| Operating I/L | 11.2M |
| Other Income/Expense | -4.1M |
| Interest Income | 0.0M |
| Pretax | 7.2M |
| Income Tax Expense | 2.5M |
| Net Income/Loss | 4.7M |
Pharming Group N.V. is a biopharmaceutical company that develops and commercializes protein replacement therapies and precision medicines for rare diseases and unmet medical needs. Its lead product, Ruconest, is a recombinant human C1 esterase inhibitor used to treat acute hereditary angioedema. The company also develops rhC1INH for pre-eclampsia, acute kidney injury, and COVID-19, leniolisib for activated PI3K delta syndrome, and alpha-glucosidase therapy for pompe and fabry diseases. Pharming Group N.V. has a development collaboration and license agreement with Novartis and a strategic collaboration agreement with Orchard Therapeutics plc for research, development, manufacturing, and commercialization of OTL-105, an investigational ex-vivo autologous hematopoietic stem cell gene therapy for hereditary angioedema.
